On the HCPLive news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.
Specific Use of Race, Ethnicity Data in Screening Model May Reduce Lung Cancer Screening Disparities
This new data indicates that there may be potential for clinicians to maintain their typical lung cancer screening model’s accuracy and also reduce racial and ethnic disparities.
Type 1 and Type 2 Diabetes Incidence Increased During COVID-19 Pandemic
September 21st 2023An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.
Psoriasis Severity Could Signal Increased Cardiovascular Risk
September 21st 2023A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.
Nehad Soloman, MD: Addressing Health Disparities in Rheumatology
Nehad Soloman, MD, believes acknowledging the cultural and social dynamics impacting patients' healthcare decisions and establishing a personal connection with patients can help overcome initial barriers to care.
Patients with IBD More Likely to Develop Gout, Study Finds
September 20th 2023Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.
Edwin H. Kim, MD: Thoughts on Intranasal Epinephrine Spray as an Alternative to EpiPen
In a new interview with the HCPLive editorial team, Edwin H. Kim, MD, spoke about the new ARS-1 (Neffy) intranasal epinephrine spray for patients having Type 1 allergic reactions as well as the FDA's upcoming decision on the treatment.